Grifols SA Faces Regulatory Scrutiny

Photo of author
Written By Faith Boluwatife

Grifols SA, a prominent player in the bio-science sector focusing on plasma therapeutics, recently encountered a major setback as its shares plummeted following a regulatory examination of its financial statements. 

This scrutiny unveiled “relevant deficiencies” within the Spanish company’s financial reporting mechanisms, though it stopped short of identifying any major accounting discrepancies.

Market Reaction and Financial Health

The company’s stock experienced a dramatic shift, dropping by as much as 9.1% in Madrid’s trading session on a Friday, contrasting with an initial rise of 8.8%. 

Credit: DepositPhotos

This downturn is part of a broader trend for Grifols, which has seen its market value halve over the course of the year. 

Additionally, the firm’s financial stability is under question, as evidenced by S&P Global Ratings’ recent downgrade due to concerns over refinancing risks.

Core Issues Identified

The regulatory body pinpointed the primary issue as the company’s handling of adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), particularly concerning non-controlling interests in other entities. 

Despite these findings, the regulator confirmed that no significant inaccuracies were detected in Grifols’ financial reports, and the company’s reported leverage ratio was found to be accurate.

Regulatory and Short-Seller Challenges

The examination into Grifols’ finances was initiated in January, following accusations from short-seller Gotham City Research, which claimed the company engaged in deceptive accounting practices and poor governance. Grifols has consistently denied these allegations. However, the controversy has adversely affected its share price and investor confidence.

Measures for Reassurance

In response to these challenges, Grifols has undertaken several initiatives aimed at restoring investor trust. 

These measures include the appointment of a new CEO and a strategic decrease in the founding family’s involvement in company operations, despite their status as the largest shareholders.

Future Commitments and Potential Sanctions

Grifols has been directed by the regulatory authority to outline steps to align its alternative performance metrics with standard financial reporting norms within 15 days. 

This includes providing enhanced disclosures regarding EBITDA and net financial debt, especially for companies where Grifols holds a non-controlling interest. Although the review’s conclusions could lead to sanctions, any decision on this matter is expected to be several months away.

Company’s Stance on Improvements

Grifols has expressed its commitment to bolstering the transparency and comprehensiveness of its financial disclosures. 

Planned improvements encompass more detailed explanations of related-party transactions, an expansion of notes in annual accounts, and a more thorough presentation of non-accounting financial performance indicators, such as EBITDA and leverage ratios.

Final Thoughts for Investors

For investors, the recent developments at Grifols SA present a complex scenario. While the regulatory review has not found significant errors in the company’s financial reporting, the identified deficiencies and the potential for future sanctions create an atmosphere of uncertainty. 

Credit: DepositPhotos

Investors should closely monitor Grifols’ forthcoming financial reports and the company’s efforts to address the regulatory concerns. The ability of Grifols to navigate these challenges effectively will be critical for its future financial health and investor confidence.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.